Patritumab Deruxtecan Shows Promise in Treating Patients with EGFR-Mutated NSCLC

2020 Year in Review - Non–Small-Cell Lung Cancer - Lung Cancer

A phase 1 clinical trial of the HER3-directed antibody–drug conjugate patritumab deruxtecan shows potential for treating patients with EGFR-mutated NSCLC.

Patients with advanced EGFR-mutated non–small-cell lung cancer (NSCLC) have a poor prognosis when EGFR tyrosine kinase inhibitors (EGFR-TKIs) and platinum-based chemotherapy fail. At the ESMO Virtual Congress 2020, researchers presented safety and efficacy results from a phase 1 clinical trial of the HER3-directed antibody–drug conjugate patritumab deruxtecan in patients with EGFR-mutated NSCLC

Patients with EGFR-mutated NSCLC and previous EGFR-TKI and platinum-based chemotherapy were enrolled in the trial. The primary objective is the assessment of activity by overall response rate as reviewed by a blinded independent central review. The secondary objective is evaluating the safety of patritumab deruxtecan administered intravenously every 3 weeks.

A total of 56 patients were evaluated for a response to 5.6 mg/kg of patritumab deruxtecan. At cutoff, 28 patients remained on treatment, and 6 of those patients had only 1 tumor evaluation. Enrolled patients had a median of 4 (range, 1-9) treatment regimens for metastatic disease. Fifty-one of the patients had received platinum-based chemotherapy prior to trial enrollment. A total of 49 patients had received osimertinib prior to trial enrollment, and the median number of EGFR-TKI treatments was 2 (range, 1-4). Twenty-seven patients had metastases of the central nervous system.

Patients were treated for a median of 3.5 months (range, 1-14 months) with a median follow-up of 5.4 months (range, 0.3-15 months). Decreased platelet counts (25%) and decreased neutrophil counts (16%) were the most common treatment-induced adverse events with a grade ≥3 rating.

Nearly all tumors had HER3 expression. Patients had various EGFR-TKI resistance mechanisms, including EGFR C797S mutation, MET amplification, HER2 mutation, BRAF fusion, and PIK3CA mutation. Patients with these various EGFR-TKI resistance mechanisms showed a response to patritumab deruxtecan treatment.

The authors concluded that patritumab deruxtecan showed promise as a safe and effective treatment in patients with advanced or metastatic EGFR-mutated NSCLC that failed EGFR-TKI or platinum-based treatments.

Reference
Yu HA, et al. ESMO 2020. Abstract LBA62.

Related Items
Antibody–Drug Conjugate Shows Promising Activity in Patients with Advanced or Metastatic EGFR Mutation–Positive NSCLC
Patricia Stewart
TOP - January 2022 Vol 15, No 1 – Online Only published on January 20, 2022 in Lung Cancer
Amivantamab plus Lazertinib Combo Improves Response in Osimertinib-Resistant EGFR-Positive NSCLC
Patricia Stewart
TOP - November 2021 Vol 14, No 7 published on November 10, 2021 in Lung Cancer
Sotorasib Shows Encouraging Activity in Patients with NSCLC and KRAS p.G12C Mutation
Patricia Stewart
TOP - September 2021 Vol 14, No 5 published on September 7, 2021 in Lung Cancer
Neoadjuvant Nivolumab plus Chemotherapy Significantly Improves Pathologic Complete Response in Patients with Resectable NSCLC
Patricia Stewart
TOP - September 2021 Vol 14, No 5 published on September 7, 2021 in Lung Cancer
Educating NSCLC Patients on Adverse Event Management
Kammi Fox-Kay, MSN, RN, AOCNS, ONN-CG(T), Cathy Simmons, RN, BSN, ONN-CG(T), Lauren Welch, MSN, NP-C, AOCNP
Videos published on July 8, 2021 in Interview with the Innovators, Lung Cancer, Adverse Events
Addressing Lung Cancer Screening Disparities in LGBT Populations
William Ackerman
TOP - May 2021 Vol 14, No 3 published on May 14, 2021 in Lung Cancer
Analysis Identifies EGFR as Most Common Mutation in Women with Lung Cancer and No Smoking History
William Ackerman
TOP - May 2021 Vol 14, No 3 published on May 14, 2021 in Lung Cancer
Cemiplimab Potential New Treatment Option for Patients with Advanced NSCLC and PD-L1 ≥50%
Patricia Stewart
TOP - January 2021 Vol 14, No 1 published on February 9, 2021 in Lung Cancer
“Astonishing Results” Seen with First-Line Lorlatinib for the Treatment of ALK-Positive NSCLC
Patricia Stewart
TOP - January 2021 Vol 14, No 1 published on February 9, 2021 in Lung Cancer
Patients with BRAF V600E–Mutant NSCLC Show Improved Overall Survival with Dabrafenib + Trametinib Combination
2020 Year in Review - Non–Small-Cell Lung Cancer published on January 29, 2021 in Lung Cancer
Last modified: July 22, 2021